-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

G-2 Building a Sickle Cell Disease Screening Program in the Republic of Uganda: The Uganda Sickle Surveillance Study (US3) with Three Years of Follow-up Screening Results

Program: Global Capacity-Building Showcase
Session: Global Capacity-Building Showcase
Sunday, December 2, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)

Charles Kiyaga1*, Arielle G. Hernandez, MPH2*, Isaac Ssewanyana, MSc1*, Kathryn E. McElhinney3*, Grace Ndeezi, PhD MMed4*, Thad A. Howard, MS5*, Christopher Ndugwa, MMed4*, Russell E. Ware, MD, PhD 3 and Jane R. Aceng, MMed MPH6*

1Central Public Health Laboratories, Kampala, Uganda
2Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
3Division of Hematology, Cancer & Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
4Department of Paediatrics and Child Health, Makerere University College of Health Sciences, Kampala, Uganda
5Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
6Ministy of Health, Republic of Uganda, Kampala, Uganda

Presentations:

Disclosures: Ware: Addmedica: Research Funding; Bristol Myers Squibb: Research Funding; Biomedomics: Research Funding; Nova Laboratories: Consultancy; Global Blood Therapeutics: Other: advisory board; Agios: Other: advisory board; Novartis: Membership on an entity's Board of Directors or advisory committees.